Search results for "Pneumococcal"

showing 10 items of 50 documents

Complement component deficiencies and infection: C5, C8 and C3 deficiencies in three families.

1992

Three families are described with complement component deficiencies. In one family, five children had C5 deficiency; in a second family, two children had C8 deficiency and one child in a third family had C3 deficiency. The index cases were identified during screening of patients with recurrent pyogenic infections, recurrent meningitis and meningococcaemia. Two of the five C5 deficient patients had recurrent meningitis and meningococcaemia, two had recurrent respiratory tract infections and otitis and one was healthy. One of the C8 deficient patients had meningitis, meningococcaemia and pneumonia, whereas his sibling with the same deficiency was healthy. The patient with C3 deficiency had fo…

MalePediatricsmedicine.medical_specialtyComplement Hemolytic Activity AssayMeningitis BacterialRecurrenceImmunopathologyRecurrent meningitisMedicineHumansSiblingChildRespiratory Tract Infectionsbusiness.industryMeningitis PneumococcalComplement C5Complement C3C5 Deficiencymedicine.diseaseComplement C8PedigreePneumoniaOtitisChild PreschoolPediatrics Perinatology and Child HealthImmunologyFemalemedicine.symptomComplicationbusinessMeningitisEuropean journal of pediatrics
researchProduct

The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-…

2003

To evaluate immune responses, safety and reactogenicity of the concomitant use of DTaP-IPV-Hib and the newly available 7-valent pneumococcal conjugate (7VPnC) vaccines when given as the primary immunization series in early infancy. A total of 231 healthy infants were enrolled at 11 German study centers and randomized to receive either 7VPnC plus DTaP-IPV-Hib vaccines concomitantly into opposite limbs at age 2, 3, 4 and 11-15 months (7VPnC group) or DTaP-IPV-Hib vaccine at the same ages plus a 7VPnC "catch-up vaccination" at ages 6, 7, 8 and 11-15 months (Control group). Blood samples were drawn before and 4 weeks after the first three vaccine doses and 4 weeks after the fourth dose. Local a…

MalePediatricsmedicine.medical_specialtyImmunization SecondaryEnzyme-Linked Immunosorbent AssayHerpesvirus VaccinesAntibodies ViralPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHerpesvirus 1 BovineReactogenicityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryDiphtheriaImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesImmunizationConcomitantChild PreschoolImmunologyMolecular MedicineFemalePertactinbusinessmedicine.drugVaccine
researchProduct

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination s…

2014

Streptococcus pneumoniae is a major cause of human infectious diseases worldwide. Despite this documented evidence, data on pneumococcal disease rates among general populations are scant because of the frequent lack of cultural identification. In this study we propose a model for estimating the burden of pneumococcal pneumonia on hospitalizations. The study was performed by analyzing administrative and clinical data of patients aged 50 years or older, resident in Sicily, and hospitalized, from 2005 to 2012. Demographic information, admission/discharge dates, discharge status, and up to 6 discharge diagnoses coded according to ICD-9 CM were collected for each hospitalized patient. During the…

MalePediatricsmedicine.medical_specialtyImmunologyPopulationSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePneumococcal VaccinesCost of IllnessHealth careStreptococcus pneumoniaemedicineHumansImmunology and AllergyeducationSicilyAgedAged 80 and overPharmacologyeducation.field_of_studySicily Streptococcus pneumoniae hospitalizations model estimating pneumococcal pneumoniabusiness.industryVaccinationBudget impactMiddle AgedPneumonia Pneumococcalmedicine.diseaseHospitalizationVaccinationPneumoniaPopulation SurveillancePneumococcal pneumoniaFemaleDiagnosis codebusinessResearch PaperHuman Vaccines & Immunotherapeutics
researchProduct

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

2013

Background: The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses when administered as 3 infant doses plus a toddler dose (3+1 schedule) or as an abbreviated schedule of 2 infant doses plus a toddler dose (2+1 schedule). The 13-valent pneumococcal conjugate vaccine (PCV13) is approved and World Health Organization-prequalified for administration in a 2+1 schedule when used as part of routine immunization programs. Objective: To summarize immunologic responses elicited by PCV13 administered in a 2+1 schedule and following 2 doses in a 3+1 schedule. Methods: Studies were double-blind, randomized, active-controlled, multicenter studies…

MaleSerotypePCV132+12+1; Immune response; PCV13; Pediatric; Pneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal conjugate vaccinePneumococcal VaccinesDouble-Blind MethodHumansMedicineDosingToddlerImmune responseMexicoPediatricGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfantAntibodies BacterialUnited KingdomClinical trialInfectious DiseasesItalySpainImmunoglobulin GConcomitantImmunologybiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drug
researchProduct

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated p…

2011

Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®) hexa/Infanrix(®)-IPV+Hib (diphtheria, tetanus, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b). After the 3-dose infant series, immunogenic noninferiority was demonstrated for all concomitantly administered antigens between the PCV13 and PCV7 groups. All antigens elicited good booster responses after the toddler dose except pertussis toxoid; however, 99.6% subjects achieved pertussis toxoid protective antibody level ≥5EU/mL in both groups. These results support the …

Malemedicine.disease_causeAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccineDrug Administration SchedulePneumococcal VaccinesAntigenDouble-Blind MethodGermanymedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaPoliovirusImmunogenicityPublic Health Environmental and Occupational HealthInfantHepatitis Bmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesTreatment OutcomeSpainbiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drugVaccine
researchProduct

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeableH…

2016

ABSTRACT Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib…

Malemedicine.medical_specialtyAntipyreticsparacetamolImmunologyIbuprofenBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causeGastroenterologyHaemophilus influenzaePneumococcal Vaccines03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineAntipyretic10-valent pneumococcal conjugateAcetaminophenfeverPharmacologyReactogenicityRomaniabusiness.industryIncidenceorganic chemicalsImmunogenicityInfantIbuprofenResearch PapersAntibodies BacterialHealthy VolunteersAcetaminophenVaccinationTreatment OutcomeImmunologyFemaleprophylaxisbusinessmedicine.drugHuman Vaccines & Immunotherapeutics
researchProduct

Comparative effects of carrier proteins on vaccine-induced immune response

2011

The efficacy of vaccines against major encapsulated bacterial pathogens -Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b (Hib) - has been significantly enhanced by conjugating the respective polysaccharides with different carrier proteins: diphtheria toxoid; non-toxic cross-reactive material of diphtheria toxin(197), tetanus toxoid, N. meningitidis outer membrane protein, and non-typeable H. influenzae-derived protein D. Hib, meningococcal, and pneumococcal conjugate vaccines have shown good safety and immunogenicity profiles regardless of the carrier protein used, although data are conflicting as to which carrier protein is the most immunogenic. Coadmini…

Meningococcal Vaccineschemical and pharmacologic phenomenamedicine.disease_causecomplex mixturesMicrobiologyPneumococcal VaccinesImmune systemAdjuvants ImmunologicConjugate vaccineStreptococcus pneumoniaemedicineHumansHaemophilus VaccinesDiphtheria toxinVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologyChemistryNeisseria meningitidisImmunogenicityPolysaccharides BacterialPublic Health Environmental and Occupational HealthToxoidVaccine efficacyVirologyInfectious DiseasesMolecular MedicineCarrier ProteinsVaccine
researchProduct

Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concent…

2011

ABSTRACT We compared the abilities of two serological readouts, antipolysaccharide IgG antibody concentrations and opsonophagocytic activity (OPA) titers, to predict the clinical effectiveness of the 7-valent pneumococcal conjugate vaccine (7vCRM) against invasive pneumococcal disease (IPD). We also assessed the accuracy of the previously established thresholds for GlaxoSmithKline's enzyme-linked immunosorbent assay with 22F adsorption (22F-ELISA) (≥0.2 μg/ml) and OPA assay (titer, ≥8) in predicting effectiveness. We showed that following a 3-dose 7vCRM primary vaccination, the serological response rates as determined using thresholds of ≥0.2 μg/ml IgG and an OPA titer of ≥8 corresponded we…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayBiologyPneumococcal conjugate vaccineImmunoglobulin GSerologyPneumococcal VaccinesImmune systemPhagocytosisHeptavalent Pneumococcal Conjugate VaccinemedicineImmunology and AllergyHumansmedicine.diagnostic_testOpsonin ProteinsVaccine ResearchVirologyAntibodies BacterialTiterImmunoassayImmunoglobulin GImmunologybiology.proteinAntibodymedicine.drugClinical and vaccine immunology : CVI
researchProduct

Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate …

2011

Background Induction of immunologic memory was assessed following primary vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Methods Infants were randomized (1:1) to receive 3 doses of PHiD-CV or 7vCRM (7-valent CRM197-conjugated pneumococcal conjugate vaccine [PCV]) at 2, 3, and 4 months of age followed by 23-valent pneumococcal polysaccharide vaccine (23vPS) booster dose at 11 to 14 months of age. Pneumococcal geometric mean antibody concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers were measured. Results Postprimary immune responses were consistent with those in previous PHiD-CV and 7vCRM studies…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsHaemophilus influenzaePneumococcal VaccinesConjugate vaccinemedicineHeptavalent Pneumococcal Conjugate VaccineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesVaccines Conjugatebusiness.industryVaccinationInfantOpsonin ProteinsPneumococcal polysaccharide vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesStreptococcus pneumoniaeTreatment OutcomeImmunizationPediatrics Perinatology and Child HealthImmunologybusinessImmunologic Memorymedicine.drugThe Pediatric infectious disease journal
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct